Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 41, 2008, Pages 15896-15901

  Zhang, Zhongyi ^a   Zhang, Yan ^a   Ning, Gang ^b   Deb, Dilip K ^a   Kong, Juan ^a   Yan, Chun Li ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Albuminuria; Glomerulosclerosis; Renin angiotensin system

Indexed keywords

ALBUMIN; ALPHA ACTININ; ANGIOTENSIN II; CREATININE; FIBRONECTIN; GLUCOSE; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PARICALCITOL; PROTEIN ZO1; RENIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DBA 2 MOUSE; DIABETIC NEPHROPATHY; ELECTRON MICROSCOPY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HISTOLOGY; HORMONE SYNTHESIS; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG COMBINATIONS; ERGOCALCIFEROLS; LOSARTAN; MICE; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; STREPTOZOCIN; VITAMIN D;

MUS;

EID: 57349185929     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0803751105     Document Type: Article

References (55)

1. Ritz E, Rychlik I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34:795-808.
2. Chan JC, et al. (2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590-600.
3. Lewis EJ, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860.
4. Brenner BM, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869.
5. Parving HH, et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878.
6. Andersen S, et al. (2000) Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606.
7. Price DA, et al. (1999) The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10:2382-2391.
8. Nishiyama A, Seth DM, Navar LG (2002) Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39:129-134.
9. Navar LG, et al. (1996) Paracrine regulation of the renal microcirculation. Physiol Rev 76:425-536.
10. Nguyen G, et al. (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109:1417-1427.
11. Lavoie JL, Sigmund CD (2003) Minireview: Overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 144:2179-2183.
12. Anderson S, Jung FF, Ingelfinger JR (1993) Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265:F477-F486.
13. Zimpelmann J, et al. (2000) Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 58:2320-2330.
14. Singh R, Singh AK, Alavi N, Leehey DJ (2003) Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14:873-880.
15. Vidotti DB, et al. (2004) High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol 286:F1039-F1045.
16. Yoo TH, et al. (2007) Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 71:1019-1027.
17. Shankland SJ (2006) The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69:2131-2147.
18. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ (2003) The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations. Diabet Med 20:607-621.
19. Carey RM, Siragy HM (2003) The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 14:274-281.
20. Li YC, et al. (2004) Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90:387-392.
21. Yuan W, et al. (2007) 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282:29821-29830.
22. Xiang W, et al. (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol 288:E125-E132.
23. Kong J, Li YC (2003) Effect of angiotensin II type I receptor antagonist and angiotensinconverting enzyme inhibitor on vitamin D receptor null mice. Am J Physiol 285:R255-R261.
24. Li YC, et al. (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238.
25. Zhang Z, et al. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73:163-171.
26. Muller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1:221-228.
27. Borghi C, et al. (1993) Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 33:40-45.
28. Roig E, et al. (2000) Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21:53-57.
29. Veniant M, et al. (1996) Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 98:1966-1970.
30. Qiao G, Kong J, Uskokovic M, Li YC (2005) Analogs of 1alpha,25- dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 96:59-66.
31. Fryer RM, et al. (2007) Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 106:76-81.
32. Li YC (2007) Inhibition of renin: An updated review of the development of renin inhibitors. Curr Opin Investig Drugs 8:750-757.
33. Qi Z, et al. (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637.
34. Breyer MD, et al. (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27-45.
35. Kawachi H, et al. (2006) Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton, Vic) 11:274-281.
36. Liebau MC, et al. (2006) Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol 290:F710-F719.
37. Gross JL, et al. (2005) Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 28:164-176.
38. Eijkelkamp WB, et al. (2007) Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18:1540-1546.
39. Azizi M, et al. (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15:3126-3133.
40. Cooper ME (1998) Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213-219.
41. Perkins BA, et al. (2007) Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 18:1353-1361.
42. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulindependent patients. N Engl J Med 311:89-93.
43. Viberti GC, et al. (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430-1432.
44. Ficociello LH, et al. (2007) Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2:461-469.
45. Kuhlmann A, et al. (2004) 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol 286:F526-F533.
46. Agarwal R, et al. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823-2828.
47. Bonnet F, et al. (2001) Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874-877.
48. Benigni A, et al. (2001) Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12:941-948.
49. Takano Y, et al. (2007) Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol 292:F1573-F1582.
50. Zhang Z, et al. (2007) 1,25-Dihydroxyvitamin D(3) targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 72:193-201.
51. Kagami S, Border WA, Miller DE, Noble NA (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437.
52. Kaneshiro Y, et al. (2006) Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 70:641-646.
53. Klaus G (2008) Renoprotection with vitamin D: Specific for diabetic nephropathy? Kidney Int 73:141-143.
54. Li YC, Bolt MJG, Cao L-P, Sitrin MD (2001) Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. Am J Physiol 281:E558-E564.
55. Taneda S, et al. (2003) Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 14:968-980.